|
| Author | Cell type | Treatment | Strain | Effect |
|
| Montero et al. | PBMC | Fluvastatin 5 μm | Heat-inactivated M. tuberculosis H37Ra 10 μg/mL | Promotes release of TH1 cytokines and promotes the activation of caspase 1 |
| Lu et al. | PBMC | Lovastatin 10 μm Fluvastatin 2 μm | M. tuberculosis antigens | Inhibits the activation of γδ T cells |
| Parihar et al. | PBMC and MDM from patients with hypercholesterolemia receiving statin therapy | Simvastatin 50 μM | M. tuberculosis H37Rv MOI 5 | Significant reduction of mycobacterial growth |
| Parihar et al. | Murine bone marrow-derived macrophages | Simvastatin 50 μM | M. tuberculosis H37Rv MOI 5 | Significant reduction of mycobacterial growth, simvastatin treatment promotes phagosomal maturation and autophagy |
| Lobato et al. | THP-1 macrophages | Rifampin 1 μg/mL plus 0.2 μM atorvastatin | M. tuberculosis H37Rv MOI 10 BCG strain of M. bovis MOI 50 | Atorvastatin has an additive effect with rifampin, reducing intracellular mycobacterial viability |
| Skerry et al. | J774 macrophage-like cells | Isoniazid 0.05 μg/mL plus 5 μM simvastatin | M. tuberculosis CDC1551 MOI 10 | Simvastatin treatment enhanced the bacterial killing activity of isoniazid at day 3 after infection |
| Dutta et al. | THP-1 macrophages | 0.011 μM isoniazid, 0.012 μM rifampicin, and 162.5 μM pyrazinamide plus 0.1 μM simvastatin | Bioluminescent M. tuberculosis H37Rv MOI 0.05 | Simvastatin treatment significantly increased the bactericidal effect of isoniazid, rifampicin, and pyrazinamide alone or in combination |
|
